ABIVAX Société Anonyme (Abivax SA) aktie
ABVX
Pre-market$129.69-2.94 (-2.22%)
Pre-Market:$83.48-46.21 (-35.63%)
Laddar diagram...
Abivax SA
Market Cap
$10,335,584,256
Öppning133.00
Högsta133.27
Lägsta128.37
Volym1.31M
P/EN/A
Börsvärde10.34B
52 veckors högsta148.83
52 veckors lägsta5.69
Genomsnittlig volym1.1M
UtdelningN/A
Beta-0.19
EPS-5.37
Om ABIVAX Société Anonyme (Abivax SA) aktie
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Företagsinformation
Börs: NasdaqGM (NGM)
Sektor: Sundhed
Industri: Bioteknologi
Adress:
7-11 Boulevard Haussmann
75009 Paris, France
75009 Paris, France
Telefon: + 33 1 53 83 09 63
Hemsida: https://www.abivax.com
Analytikernas aktierekommendationer
Denna översikt ger en snabb insikt i hur analytiker bedömer aktiens potential baserat på deras senaste analyser och kursmål.
Anbefaling:1.40 - Stærk køb
Lägsta kursmål
131.00
↑ 1.0%
Genomsnittligt kursmål
154.70
↑ 19.3%
Median kursmål
155.00
↑ 19.5%
Högsta kursmål
176.00
↑ 35.7%